Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study
Open Access
- 1 July 2003
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 89 (1) , 43-49
- https://doi.org/10.1038/sj.bjc.6600993
Abstract
Neutropenic sepsis remains a potentially life-threatening complication of anticancer chemotherapy. However, it is possible to identify patients who are at low risk for serious complications and for whom less-intensive, more-convenient treatment may be appropriate. The aim of this study was to assess the efficacy and safety of oral antibiotics in conjunction with early hospital discharge in comparison with standard in-patient intravenous antibiotics in patients with low-risk neutropenic fever. In all, 126 episodes of low-risk neutropenic fever occurred in 102 patients. Patients were randomised to receive either: an oral regimen of ciprofloxacin (750 mg 12 hourly) plus amoxicillin-clavulanate (675 mg 8 hourly) for a total of 5 days, or a standard intravenous regimen of gentamicin and tazocin (piperacillin/tazobactam) until hospital discharge. Patients randomised to oral antibiotics were eligible for discharge following 24 h of hospitalisation, if clinically stable and symptomatically improved. The efficacy of the two arms was similar: initial treatment was successful without antibiotic modification in 90% of episodes in the intravenous arm and 84.8% of episodes in the oral arm, P=0.55, absolute difference between the groups 5.2%; 95% confidence interval (CI) for the difference -7 to 17.3%. Only one episode in the oral arm was associated with significant clinical deterioration: this occurred within the initial in-patient assessment period. The median in-patient stay was 4 days in the intravenous arm (range 2-8) and 2 days in the oral arm (range 1-16 days), P&<0.0005. The reduction in hospital stay led to significant cost-savings in the oral arm. In conclusion, this study suggests that oral antibiotics in conjunction with early hospital discharge for patients who remain stable after a 24 h period of in-patient monitoring offers a feasible and cost-effective alternative to conventional management of low-risk neutropenic fever.Keywords
This publication has 33 references indexed in Scilit:
- Methodology for Clinical Trials Involving Patients with Cancer Who Have Febrile Neutropenia: Updated Guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with Emphasis on Outpatient StudiesClinical Infectious Diseases, 2002
- Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choicesSupportive Care in Cancer, 2002
- Pharmacoeconomic Analysis of Empirical Therapy with Ceftazidime Alone or Combination Antibiotics for Febrile Neutropenia in Cancer PatientsPharmacoEconomics, 1995
- Factors associated with bacteraemia in febrile, granulocytopenic cancer patientsEuropean Journal Of Cancer, 1994
- The costs of treating febrile neutropenia in six U.K. HospitalsEuropean Journal Of Cancer, 1993
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- Ceftazidime Monotherapy for Empiric Treatment of Febrile Neutropenic Patients: A MetaanalysisThe Journal of Infectious Diseases, 1991
- A Randomized Trial Comparing Ceftazidime Alone with Combination Antibiotic Therapy in Cancer Patients with Fever and NeutropeniaNew England Journal of Medicine, 1986
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983
- Fungal infections complicating acute leukemiaJournal of Chronic Diseases, 1966